Dynamic quotes: Off
|
Company Description (as filed with the SEC)
You should read the following discussion in conjunction with our consolidated financial statements as of December 31, 2012, and the notes to such consolidated financial statements included elsewhere in this Transition Report on Form 10-KT. This "Business" section contains forward-looking statements. Unless otherwise mentioned or unless the context requires otherwise (e.g., our consolidated financial statements as of December 31, 2012, and the notes to such consolidated financial statements included elsewhere in this Transition Report on Form 10-KT, or a reference to an event or circumstance that occurred prior to the effective time of the 2009 Merger on September 29, 2009), all references in this Transition Report on Form 10-KT to "the Company," "we," "our," "us" "Raptor" and similar references refer to the public company formerly known as TorreyPines Therapeutics, Inc. and now known as Raptor Pharmaceutical Corp. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.76 |
| Quarterly EPS Est: | -0.26 |
| PEG Ratio: | -.01 |
|
Mean Recommendation: View Summary / View All |
1.33 |
Data is provided by Zacks Investment Research

